Concepedia

Michael R. Migden

MR

Statistics

Publications

48

Citations

6.5K

H-Index

28

Active since

1996

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Stanford University

University of Colorado Denver

Moffitt Cancer Center

Royal North Shore Hospital

Michael R. Migden is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and dermatology.

ORCID

Top concepts

Publications per year

1996–2025

48

Publications

48

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro et al. · New England Journal of Medicine · 2012 · 1.4K citations · Full text

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

Michael R. Migden, Nikhil I. Khushalani, Anne Lynn S. Chang et al. · The Lancet Oncology · 2020 · 457 citations · Full text

, , +5

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

Michael R. Migden, Alexander Guminski, Ralf Gutzmer et al. · The Lancet Oncology · 2015 · 419 citations

, , +6

Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma

Hayley J. Sharpe, Grégoire Pau, Gerrit J.P. Dijkgraaf et al. · Cancer Cell · 2015 · 376 citations · Full text

, , +12

1–5 of 48